J Biol Chem, Vol. 274, Issue 40, 28113-28120, October 1, 1999
Polyamine Regulation of Plasma Membrane Phospholipid
Flip-Flop during Apoptosis*
Donna L.
Bratton
,
Valerie A.
Fadok,
Donald A.
Richter,
Jenai M.
Kailey,
S. Courtney
Frasch,
Tatsuji
Nakamura, and
Peter M.
Henson
From the National Jewish Medical and Research Center,
Denver, Colorado 80206
 |
ABSTRACT |
During apoptosis, phosphatidylserine
(PS) is moved from the plasma membrane inner leaflet to the outer
leaflet where it triggers recognition and phagocytosis of the apoptotic
cell. Although the mechanisms of PS appearance during apoptosis are not
well understood, it is thought that declining activity of the
aminophospholipid translocase and calcium-mediated, nonspecific
flip-flop of phospholipids play a role. As previous studies in the
erythrocyte ghost have shown that polyamines can alter flip-flop of
phospholipids, we asked whether alterations in cellular polyamines in
intact cells undergoing apoptosis would affect PS appearance, either by
altering aminophospholipid translocase activity or phospholipid
flip-flop. Cells of the human leukemic cell line, HL-60, were incubated
with or without the ornithine decarboxylase inhibitor,
difluoromethylornithine (DFMO), and induced to undergo apoptosis by
ultraviolet irradiation. Whereas DFMO treatment resulted in profound
depletion of putrescine and spermidine (but not spermine), it had no
effect on caspase activity, DNA fragmentation, or plasma membrane
vesiculation, typical characteristics of apoptosis. Notably, DFMO
treatment prior to ultraviolet irradiation did not alter the decline in PS inward movement by the aminophospholipid translocase as measured by
the uptake of 6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminocaproyl] (NBD)-labeled PS detected in the flow cytometer. Conversely, the appearance of endogenous PS in the plasma membrane outer leaflet detected with fluorescein isothiocyanate-labeled annexin V and enhanced
phospholipid flip-flop detected by the uptake of
1-palmitoyl-1-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)aminocaproyl]-sn-glycero-3-phosphocholine (NBD-PC) seen during apoptosis were significantly inhibited by prior
DFMO treatment. Importantly, replenishment of spermidine, by treatment
with exogenous putrescine to bypass the metabolic blockade by DFMO,
restored both enhanced phospholipid flip-flop and appearance of PS
during apoptosis. Such restoration was seen even in the presence
of cycloheximide but was not seen when polyamines were added externally
just prior to assay. Taken together, these data show that intracellular
polyamines can modulate PS appearance resulting from nonspecific
flip-flop of phospholipids across the plasma membrane during apoptosis.
 |
INTRODUCTION |
Under normal conditions, plasma membrane phospholipids of cells
appear to be asymmetrically distributed across the bilayer with
phosphatidylserine found almost entirely in the inner leaflet and
sphingomyelin in the outer leaflet of the bilayer (1-3). Maintenance of this asymmetry is attributed largely to the activity of
the aminophospholipid translocase that moves phosphatidylserine (PS)1 and, with a
lesser affinity, phosphatidylethanolamine from the outer to the inner
leaflet (4-7). On the other hand, the appearance of PS, seen as a
universal feature of apoptosis (3, 8, 9), and phospholipid
flip-flop during inflammatory cell activation (10-13) require
enhanced, nonspecific (with regard to head group) transbilayer movement
of phospholipids. This nonspecific transbilayer movement, or flip-flop,
of phospholipids appears to be calcium-dependent as
demonstrated in cells (neutrophils, HL-60s, Jurkats, and U937 promonocytes) undergoing apoptosis (8, 14), ionophore-treated erythrocytes/erythrocyte ghosts (15, 16), and activated platelets (10,
11). Although not yet defined, targets potentially relevant to enhanced
plasma membrane flip-flop include several integral membrane proteins,
"flippases" or "scramblases" (17-20), but also intracellular
proteases (calpain and the caspases) (9, 21-24) and transglutaminase
(12, 25, 26) that may alter membrane tethering by the submembranous
cytoskeleton. Additionally, the anionic phospholipid
phosphatidylinositol bisphosphate may play a role (27, 28). Of note, in
both the calcium-treated erythrocyte ghost (15) and the
phosphatidylinositol bisphosphate-loaded erythrocyte membrane or
vesicle (28), exogenously added polyamines, particularly spermine, have
been shown to antagonize calcium-induced nonspecific phospholipid
flip-flop. These observations in simplified models of phospholipid
flip-flop, prompted us to ask whether polyamines in intact cells might
govern the phospholipid flip-flop seen during apoptosis. By using the
ornithine decarboxylase inhibitor, DFMO, to disrupt polyamine
biosynthesis, we tested each of the processes involved in transbilayer
movement of phospholipids during cellular apoptosis. As the data show,
DFMO treatment of HL-60s resulted in characteristic progressive
depletion of intracellular spermidine and putrescine, with sparing of
spermine levels. Whereas polyamine depletion with DFMO did not alter
the decline in aminophospholipid translocase activity, inhibition of PS
appearance and phospholipid flip-flop was demonstrated with alterations
in intracellular polyamines during apoptosis. Significantly, alteration
in polyamine levels in DFMO-treated cells inhibited only the events
previously shown to require extracellular calcium (8). DFMO treatment
had no effect on calcium mobilization, scramblase or Bcl-2 expression, caspase or transglutaminase activity, plasma membrane vesiculation, or
DNA fragmentation. Importantly, repletion of spermidine levels by the
addition of putrescine to cell cultures restored phospholipid flip-flop
and the appearance of PS in the plasma membrane outer leaflet during
apoptosis. This restoration required intracellular repletion of
spermidine, as external addition of the various polyamines did not
restore PS appearance or phospholipid flip-flop. These findings
demonstrate that phospholipid flip-flop with resulting PS appearance is
dissociable from other events of apoptosis and can be governed by
cellular polyamines.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture
The human leukemia cell line HL-60 was obtained from ATCC
(Rockville, MD) and cultured in RPMI 1640 (Mediatech, Herndon, VA) supplemented with 20% heat-inactivated fetal bovine serum (Gemini Biological Products, Inc., Calabasas, CA) and maintained in the undifferentiated state at 37 °C in a 5% CO2, humidified
atmosphere. For polyamine depletion experiments, HL-60 cells were
plated at a cell density of 1.25 × 105 cells/ml in
RPMI with 20% fetal calf serum and treated with 1 mM DFMO
((2-(difluoromethyl)-DL-ornithine monohydrochloride
monohydrate), a generous gift of Dr. Ekkehard Böhme,
Hoechst-Roussel, Cincinnati, OH) and incubated 120 h at
37 °C in a 5% CO2 humidified atmosphere. Reconstitution
of polyamines was accomplished by the addition of putrescine in RPMI at
a final concentration of 10 µM at 72 and 96 h
post-seeding. Control cells were seeded at 6.25 × 104
cells/ml to accommodate a faster growth rate and were incubated under
identical conditions at the same time as the DFMO-treated cells. All
cultures were harvested while at approximately 1-1.5 × 106 cells/ml. In experiments in which protein synthesis was
inhibited by cycloheximide, the inhibitor was added at a final
concentration of 0.5 µg/ml concurrently with the initial addition of
putrescine. The cells were then incubated approximately 20 h
before harvesting. This concentration and incubation period was shown
to be sufficient to stop most of protein synthesis as determined by a
75% reduction in [35S]Cys incorporation but which
resulted in less than 10% cell death as determined by trypan blue staining.
Experimental Conditions
Cells were pelleted, resuspended in RPMI 1640 (Mediatech,
Herndon, VA) supplemented with 0.25% BSA, with or without 5 µM cytochalasin D (see below) at 2 × 106 cells/ml, and plated in 6- or 12-well plates. Apoptosis
was induced by UV irradiation at 254 nm for 5 min, and the cells were
then incubated at 37 °C in a 5% CO2 humidified
atmosphere for 2 h to allow the apoptotic phenotypes to develop
(8). At the end of the incubation period, cell cultures were
subdivided, and samples were simultaneously stained for surface
phosphatidylserine (PS) and phospholipid uptake and prepared for
polyamine analysis and DNA fragmentation (see below). Where noted,
polyamines were added externally to assess the effect on PS appearance
and phospholipid flip-flop. In these experiments, either spermidine,
putrescine, or spermine was added to a final concentration of 10 µM, 5 min before the uptake procedure commenced. The
cells were maintained in the presence of the exogenous polyamines
throughout the uptake procedure. Alternatively, cells were prepared as
above for the determination of scramblase mRNA, scramblase or Bcl-2
Western blot, or caspase or transglutaminase activity as described below.
Flow Cytometry
Propidium Iodide Staining for Apoptotic DNA--
DNA degradation
was determined by the appearance of a hypodiploid fraction in
permeabilized propidium iodide-stained cells as described previously
(8). Nuclear changes were confirmed microscopically, and DNA
fragmentation was identified by characteristic "laddering" in
agarose gels (29).
PS Detection--
Cells expressing PS in the plasma membrane
outer leaflet were identified as those binding FITC-labeled annexin V
using an Apoptosis Detection Kit (R & D Systems, Minneapolis, MN) using the manufacturer's recommendations. Under control conditions, the
binding of FITC-labeled annexin V to phosphatidylserine on the surface
of apoptotic HL-60 cells closely correlates with the appearance of
nuclear and cytoplasmic condensation by light microscopy and the
appearance of hypodiploid DNA as described previously (8). The cells
were analyzed on a Coulter XL (Miami, FL) flow cytometer, and the
results were analyzed with PC-LYSYS software (Becton Dickinson,
Franklin Lakes, NJ). Annexin-positive cells were determined as
described in the Apoptosis Kit by setting quadrants to separate viable
cells from PI-permeant cells and non-apoptotic cells from those
staining highly for the FITC-labeled annexin V probe. Percent of cells
positive for PS appearance was determined from the cells staining
greater than the control population threshold. Mean fluorescence of the
PI-impermeant cells was simultaneously determined.
Phospholipid Uptake--
Phospholipid uptake was carried out in
HEPES-buffered saline (HBS) (137 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 5 mM glucose, 10 mM HEPES, pH 7.4, with 1 mM CaCl2). Following the incubation period, cells were harvested, washed once, and resuspended in HBS (1 × 107 cells/ml). NBD-labeled phospholipids (Avanti Polar
Lipids, Alabaster, AL) were prepared by drying 1 µg of
1-palmitoyl-1- (6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)aminocaproyl]-sn-glycero-3-phosphocholine (NBD-PC) or 1 µg 1-palmitoyl-1-(6-[(7-nitro-2-1,
3-benzoxadiazol-4-yl)aminocaproyl]-sn-glycero-3-phosphoserine (NBD-PS) in a glass tube. The lipids were resuspended in 0.25% BSA
with 200 µM phenylmethylsulfonyl fluoride in HBS to a
final concentration of 50 µg/ml. Previous studies have shown that
these NBD-labeled probe lipids are readily solubilized in aqueous media containing 0.25% albumin and will partition into the plasma membrane outer leaflet (7, 12, 15). The cells (5 × 105 in 50 µl) were incubated with 1 µl of the lipid suspension and 5 µl of
50 mg/ml propidium iodide for 10 min at room temperature. Albumin
extraction of the plasma membrane outer leaflet to remove probe lipid
that had not entered the cell was performed (7, 12, 15) with 50 µl of
1% BSA in HBS for an additional 5 min. The samples were diluted with
900 µl of ice-cold HBS, transferred to an ice bath, and analyzed in
the cytofluorograph within 2 h. Early experiments demonstrated
that the signal from the cell-associated lipid is stable during this
time frame. The mean fluorescence values of the phospholipid uptakes
were determined by setting quadrants in such a manner as to separate
cells staining positively for propidium iodide (dead or highly permeant
cells) from viable cell populations. As in previous studies (4, 6),
NBD-PS was taken up quickly and was largely unavailable for albumin
extraction in control cells, as is characteristic of cells
demonstrating aminophospholipid translocase activity. In contrast to
the uptake of NBD-PS, the uptake of NBD-PC, a lipid probe not
transported by the aminophospholipid translocase was used as a marker
for "nonspecific" transbilayer movement of phospholipids that we
and others (8, 10, 11, 14-16) have shown to be dependent on calcium
minimally by control cells and remained largely available for albumin
extraction (4, 6, 7, 10-12, 15, 30). During apoptosis, uptake of
NBD-PS declines and NBD-PC increases as has been described previously
(7, 8). Metabolism of the NBD-labeled probes did not occur during the
incubation as demonstrated by TLC of cellular lipids extracted by the
acidified Bligh and Dyer method used previously (13).
In initial experiments, cells were incubated with NBD-labeled
sphingomyelin (Molecular Probes, Eugene, OR) to measure endocytosis during apoptosis, as it is thought that this lipid is internalized by
the endocytic route rather than by transbilayer flip-flop (31). For all
conditions of incubation, we saw no evidence for enhanced uptake of
NBD-SM. Additionally, endocytosis is inhibited by cytochalasin D. This
agent was used to rule out further a role for endocytosis in the uptake
of the probe lipids. The presence of cytochalasin D (5 µg/ml) (Sigma)
during incubation did not alter the uptake of either NBD-PC or NBD-PS
and so was omitted except where noted. Thus, having ruled out a role
for endocytosis of the lipid probes, NBD-labeled PS and PC uptake was
used as a measure of transbilayer phospholipid movement, either via
aminophospholipid translocase (NBD-PS) or nonspecific flip-flop
(NBD-PC), respectively (7, 12, 15).
Quantification of Intracellular Free Polyamines
At the end of the incubation period the HL-60s (1 × 106 cells in 0.5 ml) were separated from media by
centrifugation, washed once in PBS, and resuspended in 300 µl of
perchloric acid (5%). After incubation of the samples on ice for
1 h, samples were either derivatized immediately or frozen
(
20 °C) until needed. Polyamines were quantified by reverse
phase-high pressure liquid chromatography following dansyl chloride
derivatization and precolumn clean up as previously published (13).
Phospholipid Analysis
Phospholipid analysis was accomplished by lipid extraction of
107 cells utilizing an acidified Bligh and Dyer extraction
(13). The extracts were then dried under nitrogen and resuspended in isopropyl alcohol, hexane, 0.2% ammonium acetate, pH 7.0, at a ratio
of 58:40:2 (solvent A). The lipid classes were separated on a 5-µm
silica analytical column (Lichrosorb; Phenomenex, Torrance, CA)
utilizing a gradient running from 37.5 to 100% solvent B (isopropyl alcohol, hexane, 0.2% ammonium acetate, pH 7.0, at a ratio of 50:40:10) over a 20-min period at 1 ml/min. The lipid peaks were then collected and pooled representing the
phosphatidylethanolamine-phosphatidylinositol, the phosphatidylserine,
and the phosphatidylcholine peaks. Phosphorus analysis was then done on
the pooled fractions utilizing the phosphorus assay of Gerlach and
Deuticke. (32).
Calcium Mobilization
The effect of DFMO on the ability of cells to mobilize calcium
was done by the method of Lennon et al. (33) using
fura-2-acetoxymethyl ester.
Scramblase mRNA by Quantitative PCR
To determine the relative amounts of scramblase transcript in
the cells after the various treatments, mRNA was quantified using
Advantage RT-for-PCR Kit and PCR-MIMIC kit (both from
CLONTECH Laboratories Inc., Palo Alto, CA).
Briefly, cells were lysed and mRNA isolated using Trizol total RNA
isolation reagent (Life Technologies, Inc.). mRNA was
reverse-transcribed to cDNA using the Advantage RT-for-PCR kit.
Determination of scramblase mRNA quantity was done using
competitive PCR of the cDNA against a mimic DNA fragment constructed with sequences complementary to the scramblase-specific primers. These primers were 5'-GACAGCATTCCAAGGACCTCCAGGATA-3' and
5'-GCCTCTCTCAAAATTCCAGTCCAGTGC-3' which would be expected to produce a
DNA fragment corresponding to bases 59-787 of the scramblase sequence,
a fragment 729 bases long. Mimic DNA fragment primers were
5'-GACAGCATTCCAAGGACCTCCAGGATACGCAAGTGAAATCTCCTCCG-3' and
5'-GCCTCTCTCAAAATTCCAGTCCAGTGCATTTGATTCTGGACCATGGC-3' resulting in a
fragment of 560 bases. The mimic DNA fragment was quantified and
diluted to known concentrations. PCR was set up initially with the
mimic DNA fragment at 1:10 dilutions and constant amounts of the
cDNA. After PCR, the samples were run out on a 1% agarose gel, and
concentration of the mimic DNA fragment which resulted in bands of
approximately equal intensity was determined. To determine more
accurately scramblase mRNA concentration, a second dilution series
of the mimic DNA fragment was made from the next highest dilution
relative to the one that produced bands of equal intensity. This 1:2
dilution series was then also amplified, and again the mimic DNA
fragment concentration giving equivalent band intensity was determined.
This dilution corresponded to an amount of mimic DNA fragment equal to
the amount of scramblase cDNA and therefore the amount of
scramblase mRNA in the initial preparation.
Caspase Activity Assay
Intracellular caspase activity was determined utilizing the
caspase substrate
N-carbobenzyloxy-Asp-Glu-Val-Asp-(7-amino-4-trifluoromethylcoumarin (Enzyme Systems Products, Livermore, CA) which is a general
substrate used to measure the activity of caspases 3, 6, 7, 8, and 10. Cells (106/assay) were washed 1× in PBS and resuspended to
1 × 108 cells/ml in 10 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM dithiothreitol
with 1 mM phenylmethylsulfonyl fluoride and frozen. The
assay was done by mixing 2 ml of the assay buffer (100 mM HEPES, pH 7.2, 2 mM dithiothreitol, 0.1% CHAPS, and 1%
sucrose) along with the AFC-peptide substrate at 100 mM in
a cuvette and placed in an SLM 8000C spectrofluorometer with an
excitation of 400 nm and an emission of 505 nm. Following the
establishment of a baseline, the cell lysate (10 µl) was added, and
the reaction was allowed to continue for 8 min. Caspase activity was
determined as the emission value of the appearance of the free AFC
group as it was cleaved from the peptide.
Transglutaminase Assay
The determination of transglutaminase activity was done as
described previously (12).
Western Blotting
HL-60 cells (106) were harvested, pelleted, washed
1× in PBS, and resuspended in H2O with 1 mg each of
aprotinin, phenylmethylsulfonyl fluoride, and leupeptin (Sigma) and 1%
Triton X-100. Following a 15-min incubation on ice, 5 µl of each
sample was taken for total protein determination by the Bradford method
(Bio-Rad). Alternatively, the cells were harvested, washed 1× in PBS,
and lysed using nitrogen cavitation. Large cell debris was removed by
centrifugation, and then membranes were pelleted by
ultracentrifugation, and protein concentrations were determined using
BCL protein assay kit (Pierce). For the blots, equivalent amounts of
protein were separated by SDS-polyacrylamide gel electrophoresis and
transferred to a nitrocellulose membrane. After overnight blocking in
1% BSA, the blots were probed with either anti-Bcl-2 (Calbiochem) at 1 mg/ml for 1 h at room temperature or with rabbit antibodies
produced to a peptide (CESTGSQEQKSGVW) corresponding to the C-terminal extracellular portion of the scramblase gene for 2 h at room
temperature (19). The blots were washed 3× in wash buffer (25 mM Tris, pH 7.8, 190 mM NaCl, and 0.2% Tween
20) and then probed with a horseradish peroxidase-conjugated secondary
antibody. The labeled bands were detected using an ECL
chemiluminescence Western blotting kit (Amersham Pharmacia Biotech).
Cell Volume Determination
Cell volumes were analyzed with a Coulter Counter ZM connected
to a Channelyzer 256 (Coulter, Hialeah, FL).
Statistical Analysis
Data were analyzed using either a univariate or mixed effects
repeated measures analysis of variance model. When analysis of variance
indicated significance, the Tukey-Kramer HSD test for all pairs was
used to compare groups.
 |
RESULTS |
Previously, we have demonstrated that polyamines added to the
inside (but not the outside) of erythrocyte ghosts prior to resealing
inhibited nonspecific, calcium-dependent transbilayer flip-flop of phospholipids (15). These observations prompted us to ask
whether alteration of polyamine levels in intact cells during the
process of apoptosis would alter the appearance of PS in the outer
leaflet of the plasma membrane (8, 14). More specifically, we asked
whether polyamine manipulation would affect either calcium-mediated,
nonspecific phospholipid flip-flop or loss of aminophospholipid
translocase activity, both of which accompany PS appearance in
apoptosis of HL-60s (8). Treatment of HL-60s in culture with the
ornithine decarboxylase inhibitor, DFMO, resulted in progressive
depletion of intracellular spermidine and putrescine over the course of
several days. Spermine levels were initially preserved in the presence
of DFMO, a pattern typical of other cell types, and known to be
secondary to shunting of the other polyamines, putrescine and
spermidine, through the polyamine biosynthetic pathway for the
synthesis of spermine (34). Beyond the 5th day of incubation with DFMO,
spermine content did decline but resulted in unacceptable acceleration
of cell death. Experiments were therefore conducted on cultures treated
with DFMO for 5 days when nonviable cells (propidium iodide-positive)
were noted to be approximately 5%. As shown in Fig.
1, in cells cultured for 5 days with
DFMO, both putrescine and spermidine were undetectable (<5
pmol/106 cells), whereas spermine was unchanged. Given the
close correlation of polyamine levels and cell growth (35), DFMO
treatment of cultures resulted in expected slowing of cell
proliferation but no alteration in phospholipid classes, protein
content, or cell volume (see "Experimental Procedures," data not
shown). The addition of putrescine for the final 48 h of culture
to bypass the metabolic defect in DFMO-treated cultures spurred
proliferation and completely restored spermidine content, although
intracellular putrescine remained deficient (Fig. 1). Whereas
putrescine is commonly taken up by cells, neither spermidine nor
spermine added to DFMO-treated cultures restored intracellular
polyamines (34), and both were associated with substantial toxicity by
24 h.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 1.
Intracellular polyamines
(pmol/106 cells) in HL-60s incubated with and without DFMO
and putrescine in control cells (open bars) and in
cells following UV irradiation (5 min) and 2 h of culture
(shaded bars). Cultures were treated with or
without DFMO (1 mM) for 5 days. Putrescine (Put)
was added (10 µM) as shown for the final 48 h of
culture. Data are expressed as means ± S.E. n = 4. Note differences in scale for the various polyamines.
|
|
As described previously, UV irradiation (5 min) was used for the rapid
induction (2 h) of apoptosis identified by the microscopic appearance
of nuclear condensation, cell shrinkage, and plasma membrane
zeiosis. Past studies using the caspase inhibitor,
Asp-Glu-Val-Asp-fluoromethylketone, have shown complete
inhibition of both nuclear and plasma membrane changes during
UV-induced apoptosis of HL-60s, thus affirming the pivotal requirement
of caspase activation in the process of apoptosis of these cells. We
assessed caspase activity in lysates from DFMO-treated and control
cells and found it to be identical at baseline and identically elevated
after UV irradiation (Fig. 2). The
appearance of hypodiploid DNA following UV irradiation was assessed in
the flow cytometer and confirmed by the identification of DNA
fragmentation showing characteristic laddering in agarose gels (29).
DNA fragmentation in cultured cells was identical regardless of
polyamine depletion with DFMO or replenishment with putrescine addition
(Fig. 3.) Plasma membrane vesiculation,
requiring cytoskeletal assembly and characteristic of the process of
zeiosis in apoptosis, was similarly unaffected by culture conditions
and polyamine levels (Fig. 4). Thus
alteration in polyamine levels had no discernible effect on these
fundamental events of apoptosis as follows: caspase activation, DNA
fragmentation, or plasma membrane vesiculation.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 2.
Caspase activity in control (open
bars) and UV-irradiated (shaded bars)
HL-60s (expressed as fold increase over control). Cells were
incubated with or without DFMO as in Fig. 1. Data are expressed as ± S.E. n = 3.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Percent of cells undergoing apoptosis as
detected by the appearance of hypodiploid DNA in control (open
bars) and UV-irradiated (shaded bars)
HL-60s. Cells were incubated with or without DFMO and putrescine
(Put) as in Fig. 1. Data are expressed as means ± S.E.
n = 7.
|
|

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 4.
Plasma membrane vesiculation as shown by
events in the left lower quadrant of forward scatter versus side scatter plots for control (A),
UV-irradiated cells (B), UV-irradiated cells following
spermidine repletion (DFMO/putrescine) (C),
UV-irradiated cells following polyamine depletion by DFMO
(D), and cytochalasin D (CD)-treated
cells (E). Plots are representative of at least
14 experiments.
|
|
Of note, the process of apoptosis did not result in the appearance of
acetylated polyamines nor was polyamine content grossly altered
following induction of apoptosis (Fig. 1, shaded bars), as
has been reported in some cells (36, 37). A decline in putrescine
content was seen in control and putrescine-treated cells, but the
significance of this finding is hard to assess as putrescine is a
relatively minor polyamine (note scale differences in Fig. 1), and
levels were below detectability in DFMO-treated cells with or without
putrescine addition.
Loss of aminophospholipid translocase activity, an event thought to
modulate the amount of PS detectable on cells undergoing apoptosis (7,
8), was measured by the ability of cells to take up NBD-PS. PS uptake
was not altered by either spermidine/putrescine depletion or spermidine
repletion (Fig. 5) at either baseline or
following UV irradiation. The data, therefore, rule out effects of
polyamines on aminophospholipid translocase activity.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5.
Aminophospholipid translocase activity as
measured by the uptake of NBD-PS in control (open
bars) and UV-irradiated (shaded bars)
HL-60s (expressed relative to mean fluorescence of control cells
cultured without DFMO or putrescine). Cells were incubated with or
without DFMO and putrescine (Put) as in Fig. 1. Data are
expressed as means ± S.E. n = 7.
|
|
In marked contrast, the appearance of PS in the outer leaflet of the
plasma membrane was significantly altered by modulating polyamine
levels. The appearance of PS, as measured by binding of FITC-labeled
annexin V, was completely inhibited when cells were treated with DFMO
resulting in depletion of spermidine and putrescine (Fig.
6). Notably, PS appearance was restored
in cells undergoing apoptosis when spermidine content was restored by
the addition of putrescine during the last 48 h of culture (see
Fig. 1). Nonspecific phospholipid flip-flop, previously shown to be a
requirement for PS appearance during apoptosis (8), was likewise dependent on polyamine status. Nonspecific phospholipid flip-flop as
measured by NBD-PC uptake was significantly inhibited in DFMO-treated cells undergoing apoptosis (Fig. 7).
Conversely, in cells treated with DFMO followed by putrescine resulting
in spermidine repletion, enhanced NBD-PC uptake was restored. To prove
that intracellular repletion of spermidine was required for PS
appearance and nonspecific phospholipid flip-flop, spermidine (10 µM) was added exogenously for 5 min prior to lipid uptake
and found to have no effect. Likewise, putrescine or spermine added
externally just prior to lipid uptake had no effect. These findings
demonstrate the requirement for intracellular spermidine repletion for
both PS appearance in the plasma membrane outer leaflet and nonspecific
phospholipid flip-flop. Taken together, the data affirm our previous
findings (8) that during apoptosis loss of aminophospholipid
translocase activity alone is insufficient for the appearance of PS
(Fig. 5) and that PS appearance correlates with nonspecific
phospholipid flip-flop.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 6.
Appearance of PS in control and UV-irradiated
HL-60s as detected by binding of FITC-labeled annexin V. Top, histograms showing FITC-labeled annexin V binding for
control, UV-irradiated cells, UV-irradiated cells following polyamine
depletion by DFMO, and UV-irradiated cells following spermidine
repletion with DFMO/putrescine (Put). Bottom,
data expressed as mean fluorescence relative to UV-irradiated cells
cultured without DFMO or putrescine. Cells were incubated with or
without DFMO and putrescine (Put) as in Fig. 1. Appearance
of PS on UV-irradiated cells cultured with DFMO was no different than
control cells without UV irradiation and was significantly less than
appearance of PS on UV-irradiated cells cultured without DFMO or with
putrescine or DFMO/putrescine added to cultures. Data are expressed
as ± S.E. (n = 9), *p < 0.0001.
|
|

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 7.
Nonspecific transbilayer phospholipid
flip-flop as measured by uptake of NBD-PC in control (open
bars) and UV-irradiated (shaded bars)
HL-60s (expressed relative to mean fluorescence of UV-irradiated cells
cultured without DFMO or putrescine). Cells were incubated with or
without DFMO and putrescine (Put) as in Fig. 1. Uptake of
NBD-PC in UV-irradiated cells cultured with DFMO was no different than
control cells and was significantly less than uptake of NBD-PC in
UV-irradiated cells cultured without DFMO or with putrescine added to
cultures. *p < 0.0001. Data are expressed as ± S.E. n = 9.
|
|
As noted above, HL-60s undergo vesiculation and blebbing (zeiosis)
during apoptosis regardless of culture conditions (with or without DFMO
or putrescine treatment). To address the possibility that vesiculation
would alter surface area and consequently the appearance of PS and
development of phospholipid flip-flop sites, cytochalasin D, 5 µg/ml,
was added to prevent vesiculation (Fig. 4E) (8). With or
without cytochalasin D added to the cells incubated in the various
conditions, the results of lipid uptake were the same, thus controlling
for surface area changes and ruling out vesiculation as an event
required for either enhanced lipid uptake or the appearance of PS (data
not shown).
It has previously been demonstrated that extracellular calcium
(ED50 100 µM) is required for the enhanced
phospholipid flip-flop that results in PS appearance in the outer
membrane leaflet (8, 14) and that HL-60s undergoing apoptosis are
capable of transporting calcium across the plasma membrane and of
maintaining physiologic calcium concentration (8, 14, 33). Previous
reports of polyamine modulation of membrane permeability and cation
flux across membranes (38-40) and, particularly, inhibition of calcium flux from mitochondria implicated in some systems during apoptosis (41-43) prompted us to ask whether DFMO-treated cells with altered polyamine levels would show deficient calcium homeostasis.
Intracellular calcium concentrations at baseline, during apoptosis, and
mobilization with the calcium ionophore A23187 were identical in both
DFMO-treated and control cells (Table I).
Thus inhibition of nonspecific phospholipid flip-flop and PS appearance
seen in DFMO-treated cells does not appear to be related to altered
intracellular calcium homeostasis.
View this table:
[in this window]
[in a new window]
|
Table I
Intracellular calcium during apoptosis
Intracellular calcium (nM) was determined in control and
DFMO-treated HL-60s by the fura-2 method following UV irradiation.
After establishing intracellular calcium levels in cells 1 h
following UV irradiation, the calcium ionophore, A23187, was added and
calcium flux measured. Peak intracellular calcium mobilization is
shown. Data are expressed as mean ± S.E., n = 10. There were no significant differences in intracellular calcium
concentrations between control and DFMO-treated cells.
|
|
Cellular polyamine levels are highly regulated by multiple metabolic
pathways, particularly during cell proliferation and differentiation
(34, 35). Alteration of levels of cellular polyamines with DFMO has
been known to alter expression and activity of various cellular
proteins (44-46). Although the actual protein(s) involved in PS
appearance and nonspecific flip-flop have yet to be identified, we
assessed the activities or amounts of several proteins implicated in
the process of apoptosis and with the enhancement of nonspecific
transbilayer movement of phospholipids. First, scramblase mRNA was
assessed using quantitative PCR. Scramblase message was present in
DFMO-treated cells at approximately 50% that of untreated cells (Fig.
8A). However, scramblase
mRNA was not increased in cells treated with DFMO followed by
exogenous putrescine addition despite restoration of PS appearance and
calcium-mediated nonspecific flip-flop. Importantly, expression of
scramblase protein, as detected by Western blotting, was only slightly
diminished with DFMO treatment and was unchanged with putrescine
addition following DFMO treatment (Fig. 8). Similarly, transglutaminase activity was measured in lysates from DFMO-treated and control cells.
As has been shown previously (47), little activity was demonstrated in
these undifferentiated HL-60s (relative to differentiated HL-60s and
other cells), and no differences were demonstrated between DFMO-treated
cells and control cells (data not shown). Bcl-2, a survival protein
(48), was also assessed by Western blotting, as an increase in Bcl-2
might confer resistance to apoptotic membrane changes in DFMO-treated
cells. Again, no differences were demonstrated between DFMO-treated and
control cells (data not shown). In a final attempt to show that the
effects of DFMO treatment and subsequent spermidine repletion were
attributable to the polyamine manipulation, and not a particular target
protein, we treated cells with cycloheximide to inhibit protein
synthesis during incubation with putrescine. As shown in Fig.
9, cycloheximide treatment neither
altered the loss of PS appearance following UV irradiation in
DFMO-treated cells nor altered the restoration of PS appearance
following spermidine repletion. In these experiments, we observed that
treatment with cycloheximide did not have any effect on spermine or
spermidine levels following DFMO treatment, with or without putrescine
addition; they remained the same as those shown in Fig. 1 (without
cycloheximide). However, in the presence of cycloheximide, putrescine
levels as well as spermidine levels were restored in cells incubated
with putrescine. These experiments demonstrate that although
individual polyamines cannot be manipulated as in simplified membrane
models, alterations in polyamine levels, particularly spermidine, in
intact cells can govern PS appearance and nonspecific flip-flop during
cellular apoptosis (see "Discussion").

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 8.
Scramblase expression determined by Western
blotting (see "Experimental Procedures") in cells incubated in the
various conditions. Data are representative of four
experiments.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 9.
Histograms showing the appearance of PS as
detected by FITC-labeled annexin V for control (A),
UV-irradiated cells (B), UV-irradiated cells after
polyamine depletion by DFMO (C), and UV-irradiated
cells after spermidine repletion (DFMO/putrescine)
(D). Rear histograms show cells for
each condition cultured identically but with the inclusion of
cycloheximide during the final 20 h of culture. Plots are
representative of seven experiments.
|
|
 |
DISCUSSION |
In earlier work from this laboratory, we have shown that enhanced
phospholipid flip-flop and PS appearance seen during apoptosis are
entirely dependent on the presence of extracellular calcium (8).
Conversely, DNA fragmentation, plasma membrane vesiculation, and loss
of the aminophospholipid translocase activity do not require
extracellular calcium. Significantly, this dichotomy of events during
apoptosis is also seen with regard to DFMO treatment. The events
dependent on extracellular calcium, nonspecific phospholipid flip-flop,
and PS appearance are also inhibited by DFMO treatment and restored
with spermidine repletion (Figs. 1, 6, 7, and 9). Conversely, the
events independent of extracellular calcium, DNA fragmentation, plasma
membrane vesiculation, and loss of the aminophospholipid translocase
activity, proceed during apoptosis independently of whether
polyamines are altered with DFMO treatment or not (Figs. 3-5). Calcium
mobilization does not differ in DFMO-treated versus control
cells (Table I), and thus, altered calcium mobilization does not
explain the inhibition of phospholipid flip-flop and PS appearance seen
with DFMO treatment. On the other hand, polyamines are known to
antagonize the effects of divalent cations in many models (49). The
placement of DFMO treatment acting downstream of the requirement for
calcium (8) would be consistent with the data. In support of this, in a
simplified erythrocyte ghost model polyamines in a
concentration-dependent fashion inhibit calcium-induced
phospholipid flip-flop, inhibition that is overcome by increasing
calcium concentration suggesting that polyamines screen calcium from
"active flip sites" (15, 28). However, inhibition of phospholipid
flip-flop in the erythrocyte ghost model demonstrates rank ordering of
inhibition by spermine > spermidine
putrescine (15). Here
we demonstrate that depletion of spermidine and putrescine results in a
significant decrease in phospholipid flip-flop as measured by both
appearance of endogenous PS and uptake of exogenously added NBD-PC
following induction of apoptosis (Figs. 6 and 7). How then can we
reconcile the data from simplified membrane models, where levels of
each polyamine can be manipulated independently, with the current data
in intact cells undergoing apoptosis where spermidine and putrescine
are depleted together (without spermine being affected) and spermidine
alone repleted? Several possibilities are suggested. First, spermidine
and putrescine have been shown to antagonize spermine (49). As such,
DFMO treatment, resulting in putrescine and spermidine depletion, may
leave a relative enrichment of spermine that could result in enhanced screening of calcium from either anionic phospholipids such as phosphatidylinositol bisphosphate (28) and/or proteins that act as
flippases or scramblase(s) (17-19, 50). Second, intracellular pools of
polyamines (particularly cytoplasmic or submembranous) may not be
reflected in bulk intracellular measures and may be critical to the
modulating enhanced phospholipid flip-flop during apoptosis. Third,
addition of putrescine to cultures resulting in spermidine repletion
restored enhanced phospholipid flip-flop and PS appearance. Thus
spermidine may be required in a permissive fashion for the function of
a flippase. Further definition of the relative contributions of the
various polyamines awaits both more specific means to alter polyamine
species and definition of potential targets modulated by polyamines.
Aside from screening of calcium, there are other functions of
polyamines that may be relevant to explain the data. At physiologic pH,
the amino groups of the polyamines are protonated and bind negatively
charged macromolecules including nucleic acids, membrane and
cytoskeletal proteins, and anionic phospholipids. Consequences of
polyelectrolytic binding, however, are not simply a matter of charge
number (15, 49) but reflect charge density dictated by the distances
between the amines located along the flexible carbon chain. Work by
Chung et al. (51) and Meers et al. (52) determined that spermine is oriented parallel to the membrane bilayer
forming a multivalent complex with anionic phospholipids. Polyamines
with the rank order of spermine > spermidine > putrescine have been shown to "freeze" membranes by their charge interactions with both anionic phospholipids (28, 53) and cytoskeletal proteins
functioning as bridging elements (54). Implications of this binding
include steric hindrance of the bound membrane constituents,
rigidification of the bilayer polar region, and possible phase
separation of lipids in the membrane inner leaflet. As such, we would
hypothesize that spermine, without antagonism by the less charged
polyamine species, spermidine or putrescine, may inhibit lateral
mobility of membrane proteins that act as phospholipid flip sites (17,
19, 55, 56) as well as phospholipids that would otherwise be flipped
after gaining access to such proteins. Alternatively, spermine could
enhance membrane-cytoskeletal interaction by minimizing the
electrostatic repulsion of the membrane and spectrin (fodrin) (57), a
protein whose cleavage is associated with PS appearance during
apoptosis (24, 58). Recently, a 37-kDa protein, the phospholipid
scramblase, has been implicated in enhanced phospholipid flip-flop in
platelets and the erythrocyte model (18). This scramblase has been
recently cloned, purified, and shown to mediate calcium-mediated
phospholipid flip-flop (albeit at relatively low levels) when
reconstituted in proteoliposomes (19, 50). Notably, this protein when
isolated from erythrocytes and reconstituted in vesicles does not
appear to be regulated by polyamines (59). Of interest, HL-60s, unlike
several other cell lines and peripheral blood leukocytes, appear to
have relatively little expression of the scramblase protein (20).
HL-60s, nonetheless, do express PS similarly to other cells undergoing
apoptosis (8) implying either that existing scramblase activity is
adequate or that there exist other candidates for moving PS into the
outer leaflet. We note that DFMO treatment did reduce scramblase
mRNA expression by approximately 50%, but putrescine treatment,
while restoring PS appearance and phospholipid flip-flop, did not
increase scramblase mRNA. Scramblase protein expression was
affected minimally by DFMO treatment, with or without putrescine
addition (Fig. 8). Alternative candidates for flippase are members of
the multidrug resistance P-glycoprotein family (17). However, unlike
phospholipid flip-flop mediated by the multidrug resistance proteins,
we were unable to inhibit enhanced flip-flop with verapamil suggesting the multidrug resistance proteins are not candidates in this system (8,
17). Additionally, other as yet unidentified proteins have been noted
to exhibit the ability to effect phospholipid transbilayer movement
(55, 56). Thus which candidate flippase is active in HL-60s undergoing
apoptosis and whether it, or modulators of its activity (60, 61),
interacts with polyamines is the goal of future studies. We note that
several proteins, protein kinase CK2 (46, 62) and the inward rectifier
potassium channel (38, 63, 64), have binding sites for spermine and are
specifically regulated by it, thus setting precedence for polyamine
regulation of protein function.
Finally, from these data in HL-60s and in previous data from
neutrophils and Jurkat cells (8), it appears that whereas loss of the
aminophospholipid translocase may enhance the appearance of PS,
calcium-mediated phospholipid flip-flop is required for PS appearance
on the surface of apoptotic cells. Although we were unable to modulate
specifically the individual polyamines, or to deplete spermine, as can
be done using model systems, we were able for the first time to show
that modulation of polyamine levels in living cells inhibited PS
appearance and calcium-mediated nonspecific flip-flop. Recognition of
the general finding that PS appears in the plasma membrane outer
leaflet of cells undergoing apoptosis (3, 8, 9) and that PS serves as a
signal to phagocytes for distinctive, "noninflammatory" engulfment
of apoptotic cells (65-68) underscores the importance of defining the
underlying mechanism(s) for PS appearance.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Robert C. Murphy for help in
phospholipid analysis and Brenda Sebern for preparation of the manuscript.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: National Jewish
Medical and Research Center, 1400 Jackson St., Denver, CO 80206. Tel.:
303-398-1390; Fax: 303-398-1381; E-mail: brattond@njc.org.
 |
ABBREVIATIONS |
The abbreviations used are:
PS, phosphatidylserine;
DFMO, 2-(difluoromethyl)-DL-ornithine
monohydrochloride monohydrate;
FITC, fluorescein isothiocyanate;
NBD-PC, 1-palmitoyl-1-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl]aminocaproyl]-sn-glycero-3-phosphocholine;
HBS, HEPES-buffered saline;
BSA, bovine serum albumin;
PCR, polymerase
chain reaction;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic;
acid, PBS,
phosphate-buffered saline;
AFC, 7-amino-4-trifluoromethylcoumarin.
 |
REFERENCES |
| 1.
|
Op den Kamp, J. A. F.
(1979)
Annu. Rev. Biochem.
48,
47-71[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Chap, H. J.,
Zwaal, R. F. A.,
and Van Deenen, L. L.
(1977)
Biochim. Biophy. Acta
467,
146-164[Medline]
[Order article via Infotrieve]
|
| 3.
|
Zwaal, R. F. A.,
and Schroit, A. J.
(1997)
Blood
89,
1121-1132[Free Full Text]
|
| 4.
|
Sune, A.,
Bette-Bobillo, P.,
Bienvenüe, A.,
Fellmann, P.,
and Devaux, P. F.
(1987)
Biochemistry
26,
2972-2978[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Daleke, D. L.,
and Huestis, W. H.
(1985)
Biochemistry
24,
5406-5416[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Zachowski, A.,
Favre, E.,
Cribier, S.,
Hervé, P.,
and Devaux, P. F.
(1986)
Biochemistry
25,
2585-2590[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Verhoven, B.,
Schlegel, R. A.,
and Williamson, P.
(1995)
J. Exp. Med.
182,
1597-1601[Abstract/Free Full Text]
|
| 8.
|
Bratton, D. L.,
Fadok, V. A.,
Richter, D. A.,
Kailey, J. M.,
Guthrie, L. A.,
and Henson, P. M.
(1997)
J. Biol. Chem.
272,
26159-26165[Abstract/Free Full Text]
|
| 9.
|
Martin, S. J.,
Finucane, D. M.,
Amarante-Mendes, G. P.,
O'Brien, G. A.,
and Green, D. R.
(1996)
J. Biol. Chem.
271,
28753-28756[Abstract/Free Full Text]
|
| 10.
|
Tilly, R. H. J.,
Senden, J. M. G.,
Comfurius, P.,
Bevers, E. M.,
and Zwaal, R. F. A.
(1990)
Biochim. Biophy. Acta
1029,
188-190[Medline]
[Order article via Infotrieve]
|
| 11.
|
Chang, C.-P.,
Zhao, J.,
Wiedmer, T.,
and Sims, P. J.
(1993)
J. Biol. Chem.
268,
7171-7178[Abstract/Free Full Text]
|
| 12.
|
Bratton, D. L.
(1993)
J. Biol. Chem.
268,
3364-3373[Abstract/Free Full Text]
|
| 13.
|
Bratton, D. L.,
Dreyer, E.,
Kailey, J. M.,
Fadok, V. A.,
Clay, K. L.,
and Henson, P. M.
(1992)
J. Immunol.
148,
514-523[Abstract]
|
| 14.
|
Hampton, M. B.,
Vanags, D. M.,
Porn-Ares, I.,
and Orrenius, S.
(1996)
FEBS Lett.
399,
277-282[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Bratton, D. L.
(1994)
J. Biol. Chem.
269,
22517-22523[Abstract/Free Full Text]
|
| 16.
|
Williamson, P.,
Kulick, A.,
Zachowski, A.,
Schlegel, R. A.,
and Devaux, P. F.
(1992)
Biochemistry
31,
6355-6360[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
van Helvoort, A.,
Smith, A. J.,
Sprong, H.,
Fritzsche, I.,
Schinkel, A. H.,
Borst, P.,
and van Meer, G.
(1996)
Cell
87,
507-517[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Basse, F.,
Stout, J. G.,
Sims, P. J.,
and Wiedmer, T.
(1996)
J. Biol. Chem.
271,
17205-17210[Abstract/Free Full Text]
|
| 19.
|
Zhou, Q.,
Zhao, J.,
Stout, J. G.,
Luhm, R. A.,
Wiedmer, T.,
and Sims, P. J.
(1997)
J. Biol. Chem.
272,
18240-18244[Abstract/Free Full Text]
|
| 20.
|
Zhao, J.,
Zhou, Q.,
Wiedmer, T.,
and Sims, P. J.
(1998)
J. Biol. Chem.
273,
6603-6606[Abstract/Free Full Text]
|
| 21.
|
Squier, M. K. T.,
and Cohen, J. J.
(1997)
J. Immunol.
158,
3690-3697[Abstract]
|
| 22.
|
Kumar, S.
(1995)
Trends Biochem. Sci.
20,
198-202[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Enari, M.,
Talanian, R. V.,
Wong, W. W.,
and Nagata, S.
(1996)
Nature
380,
723-726[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Vanags, D. M.,
Porn-Ares, I.,
Copolla, S.,
Burgess, D. H.,
and Orrenius, S.
(1996)
J. Biol. Chem.
271,
31075-31085[Abstract/Free Full Text]
|
| 25.
|
Amendola, A.,
Gougeon, M. L.,
Poccia, F.,
Bondurand, A.,
Fesus, L.,
and Piacentini, M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
11057-11062[Abstract/Free Full Text]
|
| 26.
|
Nagy, L.,
Thomazy, V. A.,
Chandraraina, R. A. S.,
Heyman, R. A.,
and Davies, P. J. A.
(1996)
Leuk. Res.
20,
499-505[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Sulpice, J.-C.,
Zachowski, A.,
Devaux, P. F.,
and Giraud, F.
(1994)
J. Biol. Chem.
269,
6347-6354[Abstract/Free Full Text]
|
| 28.
|
Sulpice, J.-C.,
Moreau, C.,
Devaux, P. F.,
Zachowski, A.,
and Giraud, F.
(1996)
Biochemistry
35,
13345-13352[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Bratton, D. L.,
Hamid, Q.,
Boguniewicz, M.,
Doherty, D. E.,
Kailey, J. M.,
and Leung, D. Y. M.
(1995)
J. Clin. Invest.
95,
211-218
|
| 30.
|
Bratton, D. L.,
Clay, K. L.,
Kailey, J. M.,
Dreyer, E.,
Fadok, V. A.,
and Henson, P. M.
(1994)
J. Lipid Mediators
10,
43-45
|
| 31.
|
Kok, J. W.,
Babia, T.,
Klappe, K.,
and Hoekstra, D.
(1995)
Biochem. J.
309,
905-912
|
| 32.
|
Gerlach, E.,
and Deuticke, B.
(1963)
Biochem. J.
337,
477-480
|
| 33.
|
Lennon, S. V.,
Kilfeather, S. A.,
Hallett, M. B.,
Campbell, A. K.,
and Cotter, T. G.
(1992)
Clin. Exp. Immunol.
87,
465-471[Medline]
[Order article via Infotrieve]
|
| 34.
|
Pegg, A. E.
(1988)
Cancer Res.
48,
759-774[Abstract/Free Full Text]
|
| 35.
|
Casero, R. A., Jr.,
and Pegg, A. E.
(1993)
FASEB J.
7,
653-661[Abstract]
|
| 36.
|
Grassilli, E.,
Desiderio, M. A.,
Bellesia, E.,
Salomoni, P.,
Benatti, F.,
and Franceschi, C.
(1995)
Biochem. Biophys. Res. Commun.
216,
708-714[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Min, A.,
Hasuma, T.,
Yano, Y.,
Matsui-Yuasa, I.,
and Otani, S.
(1995)
J. Cell. Physiol.
165,
615-623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Williams, K.
(1997)
Cell. Signal.
9,
1-13[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Palade, P.
(1987)
J. Biol. Chem.
262,
6149-6154[Abstract/Free Full Text]
|
| 40.
|
Norris, T. M.,
Moya, E.,
Blagbrough, I. S.,
and Adams, M. E.
(1996)
Mol. Pharmacol.
50,
393-946
|
| 41.
|
Rustenbeck, I.,
Reiter, H.,
and Lenzen, S.
(1996)
Biochem. Mol. Biol. Int.
38,
1003-1011[Medline]
[Order article via Infotrieve]
|
| 42.
|
Hirsch, T.,
Marzo, I.,
and Kroemer, G.
(1997)
Biosci. Rep.
17,
67-76[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Rottenberg, H.,
and Marbach, M.
(1990)
Biochim. Biophys. Acta
1016,
77-86[Medline]
[Order article via Infotrieve]
|
| 44.
|
Igarashi, K.,
Saisho, T.,
Yuguchi, M.,
and Kashiwagi, K.
(1997)
J. Biol. Chem.
272,
4058-4064[Abstract/Free Full Text]
|
| 45.
|
Piacentini, M.,
Fesus, L.,
Farrace, M. G.,
Ghibelli, L.,
Pierdda, L.,
and Melino, G.
(1991)
Eur. J. Cell Biol.
54,
246-254[Medline]
[Order article via Infotrieve]
|
| 46.
|
Shore, L. J.,
Soler, A. P.,
and Gilmour, S. K.
(1997)
J. Biol. Chem.
272,
12536-12543[Abstract/Free Full Text]
|
| 47.
|
Davies, P. J. A.,
Murtaugh, M. P.,
Moore, W. T., Jr.,
Johnson, G. S.,
and Lucas, D.
(1985)
J. Biol. Chem.
260,
5166-5174[Abstract/Free Full Text]
|
| 48.
|
Kroemer, G.
(1997)
Nat. Med.
3,
614-620[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Schuber, F.
(1989)
Biochem. J.
260,
1-10[Medline]
[Order article via Infotrieve]
|
| 50.
|
Zhou, Q.,
Sims, P. J.,
and Wiedmer, T.
(1998)
Biochemistry
37,
2356-2360[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Chung, L.,
Kaloyanides, G.,
McDaniel, R.,
McLaughlin, A.,
and McLaughlin, S.
(1985)
Biochemistry
24,
442-452[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Meers, P.,
Hong, K.,
Bentz, J.,
and Papahadjopoulos, D.
(1986)
Biochemistry
25,
3109-3118[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Yaroslavov, A. A.,
Efimova, A. A.,
Lobyshev, V. I.,
Ermakov, Y. A.,
and Kabanov, V. A.
(1997)
Membr. Cell Biol.
10,
683-688[Medline]
[Order article via Infotrieve]
|
| 54.
|
Farmer, B. T., II,
Harmon, T. M.,
and Butterfield, D. A.
(1985)
Biochim. Biophy. Acta
821,
420-430[Medline]
[Order article via Infotrieve]
|
| 55.
|
Kean, L. S.,
Grant, A. M.,
Angeletti, C.,
Mahe, Y.,
Kuchler, K.,
Fuller, R. S.,
and Nichols, J. W.
(1997)
J. Cell Biol.
138,
255-270[Abstract/Free Full Text]
|
| 56.
|
Bezombes, C.,
Maestre, N.,
Laurent, G.,
Levade, T.,
Bettaieb, A.,
and Jaffrezou, J.-P.
(1998)
FASEB J.
12,
101-109[Abstract/Free Full Text]
|
| 57.
|
Wyse, J. W.,
and Butterfield, D. A.
(1988)
Biochim. Biophy. Acta
941,
141-149[Medline]
[Order article via Infotrieve]
|
| 58.
|
Martin, S. J.,
O'Brien, G. A.,
Nishioka, W. K.,
McGahon, A. J.,
Mahboubi, A.,
Saido, T. C.,
and Green, D. R.
(1995)
J. Biol. Chem.
270,
6425-6428[Abstract/Free Full Text]
|
| 59.
|
Stout, J. G.,
Basse, F.,
Luhm, R. A.,
Weiss, H. J.,
Wiedmer, T.,
and Sims, P. J.
(1997)
J. Clin. Invest.
99,
2232-2238[Medline]
[Order article via Infotrieve]
|
| 60.
|
Moruzzi, M.,
Barbiroli, B.,
Monti, M. G.,
Tadolini, B.,
Hakim, G.,
and Mezzetti, G.
(1987)
Biochem. J.
247,
175-180[Medline]
[Order article via Infotrieve]
|
| 61.
|
Hughes, G.,
Starling, A. P.,
East, J. M.,
and Lee, A. G.
(1994)
Biochemistry
33,
4745-4754[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Leroy, D.,
Filhol, O.,
Delcros, J. G.,
Pares, S.,
Chambaz, E. M.,
and Cochet, C.
(1997)
Biochemistry
36,
1242-1250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Shyng, S. L.,
Sha, Q.,
Ferrigni, T.,
Lopatin, A |